Program
MWN109
A development code. Also written as “MWN109 1”, “MWN109 2” and “MWN109 3”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Lepu Medical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lepu Medical | 115 open or running | phase 3since Aug 18, 2026 | Apr 14, 2025 | Mar 2027phase 2 · NCT07801820 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 14, 2025First study: phase 1 study in OverweightFirst studyNCT06938269 · 60 planned · Australia
- Aug 18, 2026Phase 3 study in OverweightPhase 3 reachedNCT07778693 · 760 planned · China
- Aug 24, 20265 phase 2 studiesNCT07791654, NCT07791537, NCT07791524 and 2 more
- Aug 24, 20264 phase 1 studiesNCT07787728, NCT07787624, NCT07787611 and 1 more
Ahead
- Mar 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07801820
- Sep 2027Primary completion: phase 3 study in OverweightNCT07778693
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07804797Overweight · China | 2 | Active, not recruiting | Sep 2026 | 71 |
| NCT07801820Diabetes Mellitus, Type 2 · China | 2 | Recruiting | Mar 2027 | 240 |
| NCT07801326Diabetes Mellitus, Type 2 · China | 1 | Completed | Aug 10, 2026 | 162 |
| NCT07791654Overweight · China | 2 | Completed | Mar 21, 2026 | 120 |
| NCT07791537Overweight · China | 2 | Active, not recruiting | Oct 2026 | 125 |
| NCT07791524Overweight · China | 2 | Completed | Jul 9, 2026 | 255 |
| NCT07787728Overweight · China | 1 | Completed | Dec 16, 2025 | 40 |
| NCT07787624Healthy Volunteers · China | 1 | Completed | Jul 20, 2025 | 48 |
| NCT07787611Healthy Volunteers · China | 1 | Completed | Dec 20, 2025 | 98 |
| NCT07778693Overweight · China | 3 | Not yet recruiting | Sep 2027 | 760 |
| NCT06938269Overweight · Australia | 1 | Recruiting | Mar 2026 | 60 |
How it is read
Names in the registry
- “MWN109 1”, 7 entries
- “MWN109 2”, 7 entries
- “MWN109 3”, 6 entries
- “MWN109 4”, 3 entries
- “MWN109 tablet”, 3 entries
Codes read as this program: MWN109.
Conditions, from the studies’ own filings
- Obesity, 7 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.